Live Breaking News & Updates on தாமதமாக உடைத்தல் மருத்துவ சோதனை
Stay updated with breaking news from தாமதமாக உடைத்தல் மருத்துவ சோதனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oral Contraceptives, Sans Beta Blockade, Raise SCD Risk in LQTS medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Top experts from Brigham and Women s Hospital presented outcomes from some of the most-anticipated clinical trials in cardiology at the virtual American College of Cardiology s 70th Annual Scientific Session. In four Late-Breaking Clinical Trial presentations, Brigham cardiologists shared their latest findings on strategies to prevent future cardiovascular events in at-risk patient populations, results of a randomized clinical trial of a statin drug among patients critically ill with COVID-19, and more. ....
ATLANTIS: Apixaban Not Superior to Standard Care After TAVR May 15, 2021 A Apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from the ATLANTIS trial presented May 15 at ACC.21 during a Late-Breaking Clinical Trial session. Researchers enrolled 1,510 patients at 50 centers in four countries (Spain, Italy, France and Germany) who underwent a successful TAVR procedure between 2016 and 2019. About one-third of the patients required anticoagulation therapy for reasons other than the TAVR procedure, mainly for atrial fibrillation (AFib). Half of this group and half of the remaining patients were randomly assigned to receive apixaban (5 mg bid). The remaining patients received standard care, which consisted of the vitamin K antagonist warfarin in patients requiring anticoagulation and an antiplatelet medication alone (typically aspirin) in those not requiring anticoagulation ....
(1) TORONTO, ON, Dec. 14, 2020 /PRNewswire/ The results of a Canadian study released this weekend provides encouraging data suggesting that the prescription strength omega-3 called icosapent ethyl (VASCEPA) may reduce inflammation and improve symptoms in patients with a diagnosis of COVID-19. This study provides the first evidence of an early anti-inflammatory effect of icosapent ethyl in symptomatic COVID-19 positive outpatients - who represent the majority of patients affected by this disease in the community , said Professor Deepak L. Bhatt, Brigham and Women s Hospital and Harvard Medical School. The study was conducted by The Canadian Medical and Surgical Knowledge Translation Research Group through an investigator-initiated grant from HLS Therapeutics and Amarin Pharmaceuticals. The study was presented by Professor Bhatt as a Late-Breaking Clinical Trial on December 12th at the National Lipid Association Conference. ....